Triclabendazole (commercial names: veterinary, liquid: Fasinex ; human, tablets: Egaten , both manufactured by Novartis) is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group. Benzimidazoles such as triclabendazole are generally accepted to bind to beta-tubulin and prevent the polymerization of the microtubules of which they are part.
Starting at
Systematic (IUPAC) name | |
---|---|
5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category | ? |
Legal status |
? |
Routes of administration | ? |
Pharmacokinetic data | |
Metabolism | oxidation to the sulfone and sulfoxide parent compound |
Biological half-life | 22 – 24 hs |
Excretion | >95% in faeces, 2% in urine, and < 1% in milk |
Identifiers | |
---|---|
CAS Number | 68786-66-3 |
ATC code | P02BX04 QP52AC01 |
PubChem | CID: 50248 |
ChemSpider | 45565 |
UNII | 4784C8E03O |
ChEMBL | CHEMBL1086440 |
Chemical data | |
---|---|
Formula | C14H9Cl3N2OS |
Molecular mass | 359.658 |
SMILES[show] |
|
InChI[show] |